NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 2.1% from a year ago
Other current liabilities stood at $14.8M at the end of Q1 FY2026, down 2.1% from a year earlier and down 37.0% from the prior quarter. Over 3 fiscal years it compounded at +691.0% a year.
Context
- Other current liabilities amounted to 124.3% of total assets at the end of Q1 FY2026, down 74.8 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -2.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.31M USD
- Year-over-year change
- +67.5%
- 4-year CAGR
- +39.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.31M | +67.5% |
| FY2024 | 2024-12-31 | 10.93M | +147.3% |
| FY2023 | 2023-12-31 | 4.42M | +11845.9% |
| FY2022 | 2022-12-31 | 37K | -99.2% |
| FY2021 | 2021-12-31 | 4.87M | — |
Other Current Liabilities vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 other current liabilities of $14.8M is the highest of the 9 companies compared; the peer median is $1.18M.
- Its year-over-year change of -2.1% is the 3rd highest of 9, against a peer median of -43.6%.
- Other current liabilities amounts to 124.3% of total assets for NRXP, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.8M | -2.1% | +691.0% | 124.3% | |
| Mar 2026 | $3.47M | +78.9% | -34.8% | 2.6% | |
| Mar 2026 | $1.94M | -37.5% | +6.0% | 0.6% | |
| Mar 2026 | $1.24M | -4.8% | +27.8% | 5.7% | |
| Mar 2026 | $1.23M | +41.5% | -4.0% | 6.2% | |
| Mar 2026 | $1.13M | -49.7% | — | 1.8% | |
| Mar 2026 | $747K | -71.4% | -29.9% | 2.4% | |
| Mar 2026 | $640K | -58.0% | +11.3% | 1.1% | |
| Jun 2026 | $0 | -100.0% | +45.1% | 0.0% | |
| Peer median (excluding NRXP) | $1.18M | -43.6% | +6.0% | 2.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.